• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CDK20 inhibition and immune checkpoint blockade: bringing cancer biology and tumour immunology together to develop novel treatment options for HCC.

作者信息

Greten Tim F, Korangy Firouzeh

机构信息

Gastrointestinal Malignancy Section, Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

出版信息

Gut. 2018 May;67(5):783-784. doi: 10.1136/gutjnl-2017-315091. Epub 2017 Oct 24.

DOI:10.1136/gutjnl-2017-315091
PMID:29066575
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6347020/
Abstract
摘要

相似文献

1
CDK20 inhibition and immune checkpoint blockade: bringing cancer biology and tumour immunology together to develop novel treatment options for HCC.细胞周期蛋白依赖性激酶20（CDK20）抑制与免疫检查点阻断：将癌症生物学与肿瘤免疫学相结合以开发肝癌的新型治疗方案。
Gut. 2018 May;67(5):783-784. doi: 10.1136/gutjnl-2017-315091. Epub 2017 Oct 24.
2
Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy.肝癌内在 CCRK 抑制作用可减弱髓源抑制性细胞的免疫抑制作用，并增强免疫检查点阻断疗效。
Gut. 2018 May;67(5):931-944. doi: 10.1136/gutjnl-2017-314032. Epub 2017 Sep 22.
3
Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time?肝癌患者的免疫治疗：是否已经准备好进入黄金时代？
Cancer Immunol Immunother. 2018 Feb;67(2):161-174. doi: 10.1007/s00262-017-2082-z. Epub 2017 Oct 20.
4
Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions.肝细胞癌中的免疫检查点阻断：当前进展与未来方向
Hepatology. 2014 Nov;60(5):1776-82. doi: 10.1002/hep.27246. Epub 2014 Sep 26.
5
Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.在肝癌微环境中鉴定决定免疫治疗疗效的肿瘤免疫屏障。
J Hepatol. 2023 Apr;78(4):770-782. doi: 10.1016/j.jhep.2023.01.011. Epub 2023 Jan 26.
6
Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects.肝细胞癌的免疫治疗：现状与未来展望
Front Immunol. 2021 Oct 4;12:765101. doi: 10.3389/fimmu.2021.765101. eCollection 2021.
7
Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.靶向单核细胞内增强子重编程提高肝癌免疫治疗疗效。
Gut. 2020 Feb;69(2):365-379. doi: 10.1136/gutjnl-2018-317257. Epub 2019 May 10.
8
Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma.调节性 T 细胞和检查点抑制在肝细胞癌中的作用。
Cancer Immunol Immunother. 2019 Dec;68(12):2055-2066. doi: 10.1007/s00262-019-02427-4. Epub 2019 Nov 13.
9
Targeted delivery of CCL3 reprograms macrophage antigen presentation and enhances the efficacy of immune checkpoint blockade therapy in hepatocellular carcinoma.CCL3 的靶向递送可重编程巨噬细胞抗原呈递并增强免疫检查点阻断疗法在肝细胞癌中的疗效。
J Immunother Cancer. 2025 Feb 23;13(2):e010947. doi: 10.1136/jitc-2024-010947.
10
Can Combined Therapy Benefit Immune Checkpoint Blockade Response in Hepatocellular Carcinoma?联合治疗能否改善肝癌的免疫检查点阻断反应？
Anticancer Agents Med Chem. 2019;19(2):222-228. doi: 10.2174/1871520618666181114112431.

引用本文的文献

1
Quantum chemical optimization and residue-specific stabilization of CDK20 inhibitors in hepatocellular carcinoma.CDK20抑制剂在肝细胞癌中的量子化学优化及残基特异性稳定作用
Mol Divers. 2025 Sep 10. doi: 10.1007/s11030-025-11339-8.
2
Deciphering and Reversing Immunosuppressive Cells in the Treatment of Hepatocellular Carcinoma.肝细胞癌治疗中免疫抑制细胞的解读与逆转
J Liver Cancer. 2020 Mar;20(1):1-16. doi: 10.17998/jlc.20.1.1. Epub 2020 Mar 31.
3
ASF1B is a Promising Prognostic Biomarker and Correlates With Immunotherapy Efficacy in Hepatocellular Carcinoma.

本文引用的文献

1
Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy.肝癌内在 CCRK 抑制作用可减弱髓源抑制性细胞的免疫抑制作用，并增强免疫检查点阻断疗效。
Gut. 2018 May;67(5):931-944. doi: 10.1136/gutjnl-2017-314032. Epub 2017 Sep 22.
2
CDK4/6 inhibition triggers anti-tumour immunity.细胞周期蛋白依赖性激酶4/6（CDK4/6）抑制可触发抗肿瘤免疫。
Nature. 2017 Aug 24;548(7668):471-475. doi: 10.1038/nature23465. Epub 2017 Aug 16.
3
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
ASF1B是一种有前景的预后生物标志物，与肝细胞癌的免疫治疗疗效相关。
Front Genet. 2022 Mar 10;13:842351. doi: 10.3389/fgene.2022.842351. eCollection 2022.
4
Liver Immune Microenvironment and Metastasis from Colorectal Cancer-Pathogenesis and Therapeutic Perspectives.肝脏免疫微环境与结直肠癌转移——发病机制与治疗前景
Cancers (Basel). 2021 May 17;13(10):2418. doi: 10.3390/cancers13102418.
5
An approach using Caenorhabditis elegans screening novel targets to suppress tumour cell proliferation.利用秀丽隐杆线虫筛选抑制肿瘤细胞增殖的新靶点的方法。
Cell Prolif. 2020 Jun;53(6):e12832. doi: 10.1111/cpr.12832. Epub 2020 May 25.
6
An inflammatory-CCRK circuitry drives mTORC1-dependent metabolic and immunosuppressive reprogramming in obesity-associated hepatocellular carcinoma.炎症性 CCRK 通路驱动肥胖相关肝细胞癌中 mTORC1 依赖性代谢和免疫抑制重编程。
Nat Commun. 2018 Dec 6;9(1):5214. doi: 10.1038/s41467-018-07402-8.
纳武利尤单抗治疗晚期肝细胞癌患者（CheckMate 040）：一项开放标签、非对照、1/2 期剂量递增和扩展试验。
Lancet. 2017 Jun 24;389(10088):2492-2502. doi: 10.1016/S0140-6736(17)31046-2. Epub 2017 Apr 20.
4
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.曲美木单抗联合消融治疗晚期肝细胞癌患者。
J Hepatol. 2017 Mar;66(3):545-551. doi: 10.1016/j.jhep.2016.10.029. Epub 2016 Nov 2.
5
Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation.致癌性mTOR信号传导招募髓源性抑制细胞以促进肿瘤起始。
Nat Cell Biol. 2016 Jun;18(6):632-44. doi: 10.1038/ncb3355. Epub 2016 May 16.
6
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy.TH1型趋化因子的表观遗传沉默塑造肿瘤免疫和免疫疗法。
Nature. 2015 Nov 12;527(7577):249-53. doi: 10.1038/nature15520. Epub 2015 Oct 26.
7
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.黑色素瘤内在的β-连环蛋白信号抑制抗肿瘤免疫。
Nature. 2015 Jul 9;523(7559):231-5. doi: 10.1038/nature14404. Epub 2015 May 11.
8
Increase in CD14+HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis.肝癌患者中 CD14+HLA-DR-/low 髓源抑制细胞的增加及其对预后的影响。
Cancer Immunol Immunother. 2013 Aug;62(8):1421-30. doi: 10.1007/s00262-013-1447-1. Epub 2013 Jun 14.
9
Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality.肝癌患者中 GARP(+)CTLA-4(+)Foxp3(+) T 调节细胞和髓源抑制细胞的频率较高与 T 细胞功能受损有关。
Cancer Res. 2013 Apr 15;73(8):2435-44. doi: 10.1158/0008-5472.CAN-12-3381. Epub 2013 Feb 19.
10
A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells.肝癌患者中一群新的髓源性抑制细胞可诱导CD4(+)CD25(+)Foxp3(+) T细胞产生。
Gastroenterology. 2008 Jul;135(1):234-43. doi: 10.1053/j.gastro.2008.03.020. Epub 2008 Mar 21.